U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

February 6, 2013

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Dear Sirs,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Novo Nordisk A/S has made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2012, which was filed with the Securities and Exchange Commission on February 6, 2013.

Sincerely,

/s/ Lars Rebien Sørensen	/s/ Jesper Brandgaard
Lars Rebien Sørensen	Jesper Brandgaard
President and Chief Executive Officer	Executive Vice President and Chief Financial Officer

Novo Nordisk A/S
Novo Allé DK-2880 Bagsværd
Denmark Telephone: +45 4444 8888

Telefax
+45 444 6626
Internet:www.novonordisk.com

CVR Number:24256790